AstraZeneca bladder cancer therapy wins NICE backing - PharmaTimes Regulator recommends durvalumab as first perioperative IO option for muscle‑invasive disease

#AstraZeneca #bladdercancer #NICE #NICErecommended #durvalumab #perioperativeIOtreatment #perioperativeimmuneoncologytreatment #muscleinvasivebladdercancer #Niagaraphase3trial #bladdercancerpatients #innovativemedicine #JeannieRigby #bladdercancercare #perioperativeDurvalumab
zurl.co/U8lNl

Timing of Durvalumab Consolidation and Survival in Non–Small Cell Lung Cancer: A Population-Based Analysis | JCO Oncology Practice PURPOSEConsolidation durvalumab after concurrent chemoradiation (CCRT) for locally advanced non–small cell lung cancer (NSCLC) extends survival. In the PACIFIC trial, the timing to initiate durvalumab...

Beneficio de añadir durvalumab en pacientes con cáncer de pulmón no microcítico es independiente de iniciarlo en o antes de la semana 4 después de la quimioirradiación #CCRT #durvalumab #NSCLC ascopubs.org/doi/abs/10.1...

DT-Real Study: Real-World Outcomes of Durvalumab With or Without Tremelimumab in Advanced HCC - OncoDaily Real-World Outcomes of Durvalumab With or Without Tremelimumab in Advanced HCC of DT-Real Study.

DT-Real Study: Real-World Outcomes of Durvalumab With or Without Tremelimumab in Advanced HCC

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Durvalumab #Tremelimumab #HCC

FDA approved Durvalumab plus FLOT for resectable gastric or GEJ adenocarcinoma - OncoDaily FDA has approved durvalumab in combination with FLOT chemotherapy as neoadjuvant and adjuvant treatment, followed by durva monotherapy.

FDA approved Durvalumab plus FLOT for resectable gastric or GEJ adenocarcinoma

@fda.gov

oncodaily.com/fda-approval...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #FDAApproval #Durvalumab

🚨: A clinical trial that resulted in a new @fda.gov approval, led by Dr. Yelena Janjigian, investigated using the immunotherapy treatment #durvalumab (INFINZI) in combination w/a standard-of-care chemotherapy regimen before & after surgery for people w/stomach & esophagus cancer.

bit.ly/3XVQC3G

POTOMAC supports add-on durvalumab for high-risk NMIBC Patients with high-risk non-muscle-invasive bladder cancer benefit from the addition of 1 year of durvalumab to BCG induction and maintenance therapy.

From #ESMO2025 - Patients with high-risk non-muscle-invasive #BladderCancer benefit from the addition of 1 year of #durvalumab to BCG induction and maintenance therapy.

Full story 👉 buff.ly/ADTAaU9

#MedNews #OncSky

#RAMPART demonstrated improved disease free suvivival at three years in resectable Renal Cell Carcinoma with addition of adjuvant #Durvalumab and #Tremelimumab

3year DFS 81% vs 73% for surveillance

Nb increased tox, including myocarditis

#ESMO25 @oncoalert.bsky.social

Durvalumab after Radiotherapy in Patients with Unresectable Stage III Non Small Cell Lung Cancer Ineligible for Chemotherapy - OncoDaily Durvalumab after radiotherapy alone in stage III NSCLC shows safety, median OS ~21 months, and ctDNA as a promising biomarker for prognosis.

Durvalumab after Radiotherapy in Patients with Unresectable Stage III Non Small Cell Lung Cancer Ineligible for Chemotherapy

oncodaily.com/new-paper-al...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Durvalumab #NSCLC #LungCancer

Real-World Study on Durvalumab in Brazilian Patients with ES-SCLC: EDUR-BRA - OncoDaily Real-World Study on Durvalumab in Brazilian Patients with ES-SCLC: EDUR-BRA / cancer, Danilo Lopes, Durvalumab, EDUR-BRA, ES-SCLC, LACOG, Latin American

Real-World Study on Durvalumab in Brazilian Patients with ES-SCLC: EDUR-BRA

oncodaily.com/insight/durv...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Durvalumab #SCLC #ES-SCLC #LungCancer #EDUR-BRA

NICE backs AstraZeneca’s dual immunotherapy for advanced liver cancer - PharmaTimes Imfinzi and Imjudo combination recommended as first-line treatment

#oncology #NICE #AstraZeneca #dualimmunotherapy #advancedlivercancer #livercancer #Imfinzi #durvalumab #Imjudo #tremelimumab #Advancedhepatocellularcarcinoma #unresectablehepatocellularcarcinoma #HCC #NICEapproval #STRIDEregimen #primarylivercancer #BritishLiverTrust
zurl.co/M3ftp

ROWAN Study of TheraSphere with Durvalumab and Tremelimumab in HCC Completed Enrollment - OncoDaily Rowan Study with Durvalumab and Tremelimumab and Therasphere in HCC completed enrollment

ROWAN Study of TheraSphere with Durvalumab and Tremelimumab in HCC Completed Enrollment

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ROWAN #TheraSphere #Durvalumab #Tremelimumab #HCC

Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer | NEJM Perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) is a standard therapy for resectable gastric and gastroesophageal junction adenocarcinomas, but recurrence rates remain hig...

Perioperative #Durvalumab in Gastric and Gastroesophageal Junction #Cancer | led to significantly #better event-free #survival: www.nejm.org/doi/full/10....

GC/GEJ-Adenokarzinom: Durvalumab ergänzt erfolgreich die perioperative Therapie Die Phase-III-Studie MATTERHORN wurde auf dem ASCO-Kongress diskutiert.

Die perioperative Gabe von #Durvalumab in Kombination mit dem FLOT-Regime senkt das Risiko für Progression, Rezidiv oder Tod bei Erkrankten mit resezierbarem Magen (GC) - oder gastroösophagealem Übergangskarzinom (GEJ) gegenüber der alleinigen FLOT-Therapie deutlich. #ASCO2025

MATTERHORN: durvalumab plus FLOT climbs to success in gastric cancer The MATTERHORN trial has shown that adding durvalumab to perioperative FLOT boosts event-free survival in people with gastric or gastroesophageal junction cancer.

From #ASCO25 - The MATTERHORN trial has shown that adding #durvalumab to perioperative FLOT boosts event-free survival in people with gastric or gastroesophageal junction cancer.

Full story 👉 buff.ly/qqyW4qk

#OncSky #GastricCancer #MedNews

#ASCO25

🔥 MATTERNHORN: adding #Durvalumab to FLOT GEJ/GC ADK resectable

🗣️ Dr. Janjigian

✅ DFS 67 vs 57% at 24m HR 0.71
✅ mOS 76 vs 70% at 24m
✅ pCR 19 vs 7%
90% PD-L1+

#OncoNexion25
@oncoalert.bsky.social
@ascocancer.bsky.social @vhio.bsky.social
@myesmo.bsky.social

Oncology's Green Light Podcast · OncologyResearch · FDA Approvals: AI-Powered Insights for everyday oncology clinicians

🎧 Stay informed and join the conversation! #BladderCancer #Oncology #Immunotherapy #FDA #Durvalumab #NIAGARA
open.spotify.com/show/6yKyfXw...

Durvalumab (Imfinzi): Uses in Cancer, Side effects, Dosage, Expectations and More - OncoDaily Explore Durvalumab (Imfinzi): how it works, cancer types it treats, dosage, side effects, clinical trial insights, and what patients can expect.

Durvalumab (Imfinzi): Uses in Cancer, Side effects, Dosage, Expectations and More

oncodaily.com/drugs/durval...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Durvalumab #Imfinzi

Comparing #durvalumab, #olaparib, and #cediranib, or chemotherapy in platinum-resistant #ovariancancer: the @nrgonc.bsky.social GY023 trial

url:aacrjournals.org/clincancerres/article-ab...

#gyncsm

Exploratory Post Hoc Analysis of DUO-E Reveals Olaparib’s Benefit in Endometrial Cancer Subsets The phase III DUO-E study evaluated the addition of the monoclonal antibody durvalumab to chemotherapy, and the benefit of maintenance durvalumab, with and without the PARP inhibitor olaparib, in adva...

Adding #Olaparib to chemo + #Durvalumab significantly boosts progression-free survival in the pMMR subgroup. Key findings: benefit across biomarkers & ctDNA detection. What’s next for personalized treatment?

🔗 ascopost.com/issues/march...

#Oncology #CancerResearch

Comparative Efficacy of Immunotherapy-based treatment versus Chemotherapy-only in Patients with Unresectable NSCLC with Disease Progression Post Chemoradiation and Durvalumab The current standard of care for fit patients with unresectable stage III NSCLC involves concurrent chemoradiation (CRT) followed by durvalumab. Disease recurrence occurs in approximately 2/3 of patie...

PFS≥12 on #durvalumab might be a positive predictive factor for ICB re-treatment
#nsclc #lcsm

www.ejcancer.com/article/S095...

🚀 Key #UrothelialCancer abstracts from #ASCOGU!
📌 Abstract 661 – #Durvalumab (#MEDI4736) + neoadjuvant chemo (#Gemcitabine + #Cisplatin / #Carboplatin) in high-risk upper tract urothelial carcinoma.
📌 Abstract 667 – #Durvalumab + intravesical #Gemcitabine & #Docetaxel in #BCG-unresponsive NMIBC.

AstraZeneca receives positive recommendations for lung cancer treatments - PharmaTimes NICE endorses Imfinzi and Tagrisso for enhanced lung cancer care

#AstraZeneca #lungcancer #NICE #Imfinzi #durvalumab #Tagrisso #osimertinib #NICEpositiverecommendation #NICErecommendation #NHSEngland #NHSWales #ESSCLC #CASPIANPhaseIIItrial #overallsurvivalbenefits #ThoracicOncology #NSCLC #ADAURAphase3trial
pharmatimes.com/news/astraze...

2024 approvals: Summary of 14 new drugs/indications in #LungCancer by FDA

1. #Tepotinib
2. #Osimertinib x2
3. #Alectinib
4. #Tarlatamab
5. #Zenocutuzumab
6. #Durvalumab x2
7. #Amivantamab x2
8. #Nivolumab (now SubQ)
9. #Ensartinib

#lcsm #OncSky #MedSky #Cancer

Gemcitabine Cisplatin and Durvalumab Experience in Advanced Biliary Tract Cancers: A Real-World, Multicentric Data From India | JCO Global Oncology PURPOSEBiliary tract cancers (BTCs) are usually diagnosed in advanced stages, where treatment options are either palliative chemotherapy and/or best supportive care. The breakthrough results of the TO...

Durvalumab mejora la eficacia y seguridad de la quimioterapia en pacientes con cáncer avanzado metastásico del tracto biliar, especialmente en la vesícula biliar BTC #durvalumab ascopubs.org/doi/full/10....

Imfinzi receives NICE recommendation for lung cancer treatment - PharmaTimes Trial results lead to new treatment option for lung cancer

#oncology #Imfinzi #durvalumab #AstraZeneca #NICErecommendation #lungcancer #lungcancerpatients #lungcancertreatment #resectablenonsmallcelllungcancer #NSCLC #AEGEANphase3trial #NHS #NSCLCpatients #ThoracicOncology #patientoutcomes #AEGEANtrial
pharmatimes.com/news/imfinzi...

FDA approves durvalumab for limited-stage small cell lung cancer - OncoDaily FDA approves durvalumab for limited-stage small cell lung cancer / Australian Therapeutic Goods Administration, Brazilian Health Regulatory Agency, Byoung

FDA approves durvalumab for limited-stage small cell lung cancer

oncodaily.com/blog/fda-198...

fda.gov

#Cancer #Durvalumab #EuropeanMedicinesAgency #FDA #Health #OncoDaily #Oncology #SmallCellLungCancer

Durvalumab Wins FDA Approval in Limited-Stage Small Cell Lung Cancer The approval of durvalumab, based on data from the phase 3 ADRIATIC study, offers a new standard of care for patients with limited-stage small cell lung cancer.

#Durvalumab Wins #FDA Approval in Limited-Stage Small Cell #LungCancer www.targetedonc.com/view/durvalu... via @targetedonc

Cetuximab Outperforms Durvalumab in Treatment of Head and Neck Cancers The standard treatment for head and neck cancer, cisplatin, can’t be given to some patients due to pre-existing conditions. A new study compares the efficacy of two alternatives: cetuximab, a monoclon...

The standard treatment for head and neck #cancer, cisplatin, can’t be given to some patients due to pre-existing conditions. A new study compares the efficacy of two alternatives: #cetuximab & #durvalumab. @ucsdmedschool.bsky.social @ucsdhealth.bsky.social

today.ucsd.edu/story/cetuxi...

FDA approves pembrolizumab with chemotherapy for biliary ... FDA approves pembrolizumab with chemotherapy for biliary ...

#pembrolizumab joins #durvalumab as another ⁦@US_FDA⁩ approved
option in combination with chemo for biliary tract cancer ⁦@curecc⁩ ⁦@CCA_Alliance⁩ www.fda.gov/drugs/resources-informat...

1L systemic therapy for iCCA should be gem/cis plus #durvalumab where available per @EASLedu @ILCAnews
iCCA guidelines. Other targeted therapies depending on molecular profiling apply #LiverCancerSummit @curecc